MSB 2.17% $1.13 mesoblast limited

Cell Therapy News/Articles, page-774

  1. 5,344 Posts.
    lightbulb Created with Sketch. 956
    Gan Gans , I do notice you are an avid poster and holder of a company whose main focus Is as follows
    “Our main focus is on repurposing PPS (under the name ZILOSUL® to treat Osteoarthritis (OA) – market with over 31m sufferers in the US alone” ...............................................................................And no doubt you will be aware of this ................................................................................
    Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 2a trial of its Mesenchymal Precursor Cells (MPCs) for prevention of radiographic and clinical features of knee osteoarthritis after traumatic injury has been published in the peer-reviewed journal Arthritis Research & Therapy. The results showed that a single intra-articular injection of Mesoblast’s product candidate MPC-75-IA reduced cartilage loss and bone changes by six months, and improved pain and function for over two years, when compared to controls.......................................Could this be the reason you are posting on the Mesoblast Thread ?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.